A detailed history of Wellington Management Group LLP transactions in Nuvalent, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 1,011,837 shares of NUVL stock, worth $88.5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,011,837
Previous 611,435 65.49%
Holding current value
$88.5 Million
Previous $46.4 Million 123.16%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$67.44 - $112.17 $27 Million - $44.9 Million
400,402 Added 65.49%
1,011,837 $104 Million
Q2 2024

Aug 13, 2024

BUY
$62.76 - $81.61 $1.12 Million - $1.46 Million
17,833 Added 3.0%
611,435 $46.4 Million
Q1 2024

May 15, 2024

BUY
$72.35 - $88.99 $42.9 Million - $52.8 Million
593,602 New
593,602 $44.6 Million
Q4 2023

Feb 12, 2024

BUY
$42.42 - $80.28 $43 Million - $81.4 Million
1,013,402 New
1,013,402 $74.6 Million
Q3 2023

Nov 14, 2023

SELL
$39.12 - $49.85 $7.05 Million - $8.98 Million
-180,120 Reduced 10.37%
1,556,367 $71.5 Million
Q2 2023

Aug 14, 2023

SELL
$23.58 - $44.68 $3.54 Million - $6.71 Million
-150,189 Reduced 7.96%
1,736,487 $73.2 Million
Q1 2023

May 12, 2023

BUY
$25.42 - $33.52 $11.4 Million - $15.1 Million
450,287 Added 31.35%
1,886,676 $49.2 Million
Q4 2022

Feb 13, 2023

BUY
$18.46 - $36.37 $8.98 Million - $17.7 Million
486,422 Added 51.2%
1,436,389 $42.8 Million
Q3 2022

Nov 14, 2022

SELL
$13.55 - $19.92 $755,263 - $1.11 Million
-55,739 Reduced 5.54%
949,967 $18.5 Million
Q1 2022

May 16, 2022

SELL
$11.65 - $19.57 $90,485 - $152,000
-7,767 Reduced 0.77%
1,005,706 $14 Million
Q4 2021

Feb 11, 2022

SELL
$18.01 - $30.1 $650,124 - $1.09 Million
-36,098 Reduced 3.44%
1,013,473 $19.2 Million
Q3 2021

Nov 15, 2021

BUY
$18.25 - $38.35 $19.2 Million - $40.3 Million
1,049,571 New
1,049,571 $23 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.76B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.